Study May Help Physicians Determine How Patients Will Respond to Immunomodulator Therapy for Multiple Myeloma
Sunday, December 11, 2011 - 12:00
in Health & Medicine
Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona.
